Article Text

PDF
10 Certolizumab pegol inhibits tumour necrosis factor-induced endothelial cell activation
  1. S K Heathfield1,2,
  2. I Bruce1,
  3. M Y Alexander2
  1. 1Arthritis Research UK Epidemiology Unit, School of Translational Medicine, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK
  2. 2Cardiovascular Research Group, School of Biomedicine, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK

Abstract

Rationale Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis and premature cardiovascular death. Chronic inflammation mediated by tumour necrosis factor (TNF) may contribute to this by promoting endothelial activation, dysfunction and leukocyte recruitment. Anti-TNF therapy has been associated with improved vascular function in RA patients. However, the specific effects of TNF inhibitors on endothelial cell function are largely unknown. We aim to establish whether the anti-TNF therapy certolizumab pegol (CZP) (Cimzia®; UCB, Belgium) modulates the inflammatory response by activated human endothelial cells.

Methods and Results Human aortic endothelial cells (HAoECs) were cultured in vitro and exposed to (i) TNF alone, (ii) TNF plus CZP, or (iii) neither agent. Microarray analysis detected at least twofold higher expression of 115 genes after exposure of HAoEC to TNF, compared to control untreated cells. 22.6% of the increased genes were associated with the immune response and 9.6% encoded adhesion/cell surface molecules. In particular, genes for E-selectin, VCAM-1 and ICAM-1 were significantly upregulated by TNF treatment, which was validated by qPCR. Notably, treatment of HAoEC with the TNF/CZP cocktail prevented the up-regulation of these genes, resulting in an expression pattern similar to that detected in control cells. Immunocytochemistry confirmed the NFkB pathway as a downstream target of TNF-induced HAoEC activation, since the TNF-induced nuclear translocation of NFkB was prevented in the presence of CZP.

Conclusions The clinically available anti-inflammatory agent CZP eliminates upregulation of adhesion molecules by endothelial cells. Whether this TNF inhibitor contributes to improved endothelial function in patients is currently under investigation.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.